Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most included discontinuation-related safety counseling statements align with the provided label excerpts (5.6 and 2.4 and patient counseling). Several specific symptom/urgency claims (e.g., agitation/anxiety/insomnia/nausea/sweating/pain and specific urgent-care triggers) are not supported by the provided label text, and contraindications/warnings/boxed warnings/drug interactions/adverse reactions beyond discontinuation are not evaluated.
Category Scores
Accurate Statements
Antiepileptic drugs should not be abruptly discontinued because of the possibility of increasing seizure frequency.
5.6 Increased Risk of Seizures and Other Adverse Reactions with Abrupt or Rapid Discontinuation: “Antiepileptic drugs should not be abruptly discontinued because of the possibility of increasing seizure frequency.”
When NEURONTIN is being discontinued, the dose should be tapered over at least a one-week period.
5.6: “When NEURONTIN is being discontinued, the dose should be tapered over at least a one-week period.”
After discontinuation of short-term and long-term treatment with gabapentin, withdrawal symptoms have been observed in some patients.
5.6: “After discontinuation of short-term and long-term treatment with gabapentin, withdrawal symptoms have been observed in some patients …”
Suicidal behavior and ideation can be reported in patients after discontinuation of NEURONTIN.
5.6: “Suicidal behavior and ideation have also been reported in patients after discontinuation of NEURONTIN …”
Elderly patients are more likely to have decreased renal function; care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values.
2.4 Dosage in Elderly: “Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values…”
Patients should be advised to neither drive a car nor operate other complex machinery until they have gained sufficient experience on NEURONTIN to gauge whether it affects their mental and/or motor performance adversely.
17 PATIENT COUNSELING INFORMATION (Dizziness and Somnolence and Effects on Driving and Operating Heavy Machinery): “advise them neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on NEURONTIN…”
Suicidal thoughts and behavior can appear even after NEURONTIN has been discontinued.
17 PATIENT COUNSELING INFORMATION (Suicidal Thinking and Behavior): “Also, inform patients who plan to or have discontinued NEURONTIN that suicidal thoughts and behavior can appear even after the drug is stopped.”
Unsupported Statements
People may experience agitation after abrupt stopping of gabapentin.
The provided label excerpts do not list agitation as a discontinuation symptom.
People may experience anxiety after abrupt stopping of gabapentin.
The provided label excerpts do not list anxiety as a discontinuation symptom.
People may experience insomnia after abrupt stopping of gabapentin.
The provided label excerpts do not list insomnia as a discontinuation symptom.
People may experience nausea after abrupt stopping of gabapentin.
The provided label excerpts do not list nausea as a discontinuation symptom.
People may experience pain after abrupt stopping of gabapentin.
The provided label excerpts do not list pain as a discontinuation symptom.
People may experience sweating after abrupt stopping of gabapentin.
The provided label excerpts do not list sweating as a discontinuation symptom.
Abrupt stopping of gabapentin can trigger a rebound increase in seizures in people taking it for epilepsy.
The provided label excerpt states abrupt discontinuation can increase seizure frequency, but does not specifically describe “rebound increase” phrasing.
The safest approach to discontinuing gabapentin is usually tapering off rather than stopping at once.
The label excerpt specifies tapering over at least one-week period, but does not use “safest approach” language.
Avoid stopping gabapentin suddenly unless a clinician specifically tells you to.
The label excerpt states antiepileptic drugs should not be abruptly discontinued; it does not include the conditional “unless a clinician specifically tells you to” wording.
A typical taper plan for gabapentin depends on the dose, how long it has been taken, and why it is being taken.
The provided label excerpt specifies at least a one-week taper but does not describe factors for a “typical taper plan.”
A prescriber can set a schedule to lower the gabapentin dose gradually over time to reduce withdrawal or rebound symptoms.
The excerpt supports tapering to discontinue and observes withdrawal symptoms, but does not mention “rebound symptoms” or a prescriber-set schedule framed this way.
If you miss a few doses of gabapentin, do not double up to catch up.
The provided label excerpts do not address missed dose instructions.
If you miss doses, contact your pharmacy or prescriber for guidance on what to do next.
The provided label excerpts do not address missed dose instructions.
If you have missed enough doses that stopping suddenly is likely, it is better to ask for a plan rather than abruptly stopping or changing dose on your own.
The provided label excerpts do not address scenarios involving missed doses.
Get urgent medical care if you have severe agitation after missed or abrupt stopping of gabapentin.
The provided label excerpts do not specify urgent-care criteria for agitation related to missed/abrupt stopping.
Get urgent medical care if you have confusion after missed or abrupt stopping of gabapentin.
The provided label excerpts do not specify urgent-care criteria for confusion related to missed/abrupt stopping.
Get urgent medical care if you have uncontrolled vomiting after missed or abrupt stopping of gabapentin.
The provided label excerpts do not specify urgent-care criteria for vomiting related to missed/abrupt stopping.
Get urgent medical care if you have any seizure activity after missed or abrupt stopping of gabapentin.
While seizures are discussed in relation to abrupt discontinuation, the provided excerpts do not provide this specific urgent-care instruction tied to missed/abrupt stopping.
If you have epilepsy or any history of seizures, missed or abrupt stopping of gabapentin is higher risk.
The provided label excerpt discusses increased seizure frequency with abrupt discontinuation but does not provide this specific “history of seizures” risk framing for missed/abrupt stopping.
If you have epilepsy or any history of seizures, contact a clinician promptly regarding missed or abrupt stopping of gabapentin.
The provided label excerpts do not include this specific counseling instruction.
Contradictions
Important Omissions
Boxed warnings/contraindications/drug interactions and broader warnings and precautions are not assessed in the claims provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some highly specific symptom and urgent-care/missed-dose instructions are unsupported by the provided label excerpts, which could lead to over- or under-escalation. Core discontinuation guidance related to seizure risk and taper duration is supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Multiple discontinuation-related symptom examples and missed-dose/urgent-care instructions are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to the label-supported concepts in the provided excerpts (no abrupt discontinuation; taper over at least one week; withdrawal symptoms observed; seizure frequency increase risk with abrupt discontinuation; suicidal behavior/ideation may occur after discontinuation) and remove or rephrase unsupported specific symptom/urgency/missed-dose claims unless corroborated by additional label text.